UK regulatory agency clears prostate drug Flomax for OTC use; generic competition due next year in USA
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has recently approved of the first over-the-counter (OTC) medicine to treat the symptoms of benign prostatic hyperplasia (BPH) in men, to be available through pharmacies without a prescription.
The drug in question, tamsulosin capsules, will be available to buy under the brand name Flomax Relief, for short-term use in men aged 45 to 75 following a consultation with a pharmacist. Tamsulosin was originated by Japan's Yamanouchi, now part of Astellas, and is marketed by licensee Boehringer Ingelheim of Germany
An estimated one-in-four men over the age of 40 suffer from BPH, the progressive enlargement of the prostate gland. Symptoms include urinary hesitancy, weak stream, and frequent urination, including at night.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze